Trending...
- Paranormal Show, Mass Hauntings, Set to Premiere New Episode on Cafe Venice
- InventHelp Inventor Develops Versatile Pair of Skates (BEC-193)
- Boston Public Health Commission Provides Update on City's COVID-19 Trends
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022.
A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
More on Boston Chron
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
More on Boston Chron
Contacts
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
More on Boston Chron
- Boston: Gaby Germanos Named Chief of Staff for the Equity and Inclusion Cabinet
- Boston: Heat Emergency Extended Through Tuesday, 16 BCYF Cooling Centers Continue to Be Open
- Boston: Mayor Wu Extends Heat Emergency Through Tuesday, 16 BCYF Cooling Centers Continue to Be Open for All Residents
- YUPRO and OpenClassrooms Introduce U.S. Department of Labor Registered Apprenticeship Program
- Boston: MAYOR WU APPOINTS OLIVER SELLERS-GARCIA AS BOSTON GREEN NEW DEAL DIRECTOR
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
More on Boston Chron
- Triverus Consulting Welcomes Lisa Burgese Fry as Director of Business Development
- Gospel Charting Artist Jeremiah Nedu Is On The Rise With New Single "Your Mercy"
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
- Peer-Reviewed Study Shows Measurable Impact on Employee Health and Productivity from Employee Assistance Program
- HWS Announces Top 10 Low Cost Vacation Spots
Contacts
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
Filed Under: Business
0 Comments
Latest on Boston Chron
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- ZSuite Tech Secures $11 Million in Series A Round, Led by S3 Ventures
- Motif FoodWorks Appoints Michael Leonard as CEO
- Acushnet Holdings Corp. Announces Second Quarter 2022 Financial Results
- Climate Smart Buildings Initiative Positions Federal Government for Clean Energy Transformation Through Energy Savings Performance Contracts
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- Adam Ritchie Empowers PR Pros with "Invention in PR" Book
- OneScreen.ai Launches Most Comprehensive Public Directory
- Zonit Launches the World's Best Automatic Transfer Switch for Industrial & Commercial Applications
- Boston: Mayor Wu Declares Heat Emergency, Opens 16 BCYF Cooling Centers to All Residents
- The TJX Companies, Inc. to Report Q2 FY23 Results August 17, 2022
- Bridget Rose Productions is producing the short documentary - "FORCE" RECON
- City of Boston Files Ordinance to Update Flag Raising Policy
- Boston: Open Streets Traffic Advisory for August 6, 2022
- 2seventy bio to Participate in Upcoming Investor Conferences
- Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
- Paranormal Show, Mass Hauntings, Set to Premiere New Episode on Cafe Venice
- Uncle Sam Rounseville & wife Jean Kenney, donate 25 scholarships to Quincy's Roundball Basketball